AKERO THERAPEUTICS ($AKRO) posted quarterly earnings results on Friday, August 8th. The company reported earnings of -$0.86 per share, beating estimates of -$0.91 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $AKRO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AKERO THERAPEUTICS Insider Trading Activity
AKERO THERAPEUTICS insiders have traded $AKRO stock on the open market 79 times in the past 6 months. Of those trades, 3 have been purchases and 76 have been sales.
Here’s a breakdown of recent trading of $AKRO stock by insiders over the last 6 months:
- ANDREW CHENG (President and CEO) has made 0 purchases and 17 sales selling 196,195 shares for an estimated $9,157,175.
- G. WALMSLEY GRAHAM has made 3 purchases buying 200,000 shares for an estimated $8,787,921 and 0 sales.
- TIMOTHY ROLPH (Chief Scientific Officer) has made 0 purchases and 21 sales selling 104,003 shares for an estimated $5,092,141.
- CATRIONA YALE (Chief Development Officer) has made 0 purchases and 17 sales selling 64,123 shares for an estimated $3,023,439.
- JONATHAN YOUNG (Chief Operating Officer) has made 0 purchases and 5 sales selling 54,553 shares for an estimated $2,484,742.
- PATRICK LAMY (Senior VP, Commercial Strategy) has made 0 purchases and 12 sales selling 22,794 shares for an estimated $1,100,720.
- WILLIAM RICHARD WHITE (Chief Financial Officer) has made 0 purchases and 3 sales selling 5,114 shares for an estimated $271,349.
- SCOTT A. GANGLOFF (Chief Technology Officer) sold 848 shares for an estimated $46,504
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AKERO THERAPEUTICS Hedge Fund Activity
We have seen 159 institutional investors add shares of AKERO THERAPEUTICS stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 1,784,562 shares (+479.9%) to their portfolio in Q1 2025, for an estimated $72,239,069
- DEEP TRACK CAPITAL, LP added 1,720,270 shares (+115.5%) to their portfolio in Q1 2025, for an estimated $69,636,529
- WELLINGTON MANAGEMENT GROUP LLP removed 1,440,721 shares (-19.5%) from their portfolio in Q1 2025, for an estimated $58,320,386
- MARSHALL WACE, LLP added 1,332,768 shares (+484.5%) to their portfolio in Q1 2025, for an estimated $53,950,448
- BELLEVUE GROUP AG added 1,250,666 shares (+inf%) to their portfolio in Q1 2025, for an estimated $50,626,959
- JANUS HENDERSON GROUP PLC added 1,034,409 shares (+17.1%) to their portfolio in Q1 2025, for an estimated $41,872,876
- FMR LLC added 970,403 shares (+2505.9%) to their portfolio in Q1 2025, for an estimated $39,281,913
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AKERO THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $AKRO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 08/04/2025
- B of A Securities issued a "Buy" rating on 05/27/2025
- Citigroup issued a "Buy" rating on 05/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/03/2025
To track analyst ratings and price targets for AKERO THERAPEUTICS, check out Quiver Quantitative's $AKRO forecast page.
AKERO THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $AKRO recently. We have seen 4 analysts offer price targets for $AKRO in the last 6 months, with a median target of $75.5.
Here are some recent targets:
- Ritu Baral from TD Cowen set a target price of $76.0 on 08/04/2025
- Alexandria Hammond from B of A Securities set a target price of $64.0 on 05/27/2025
- Jonathan Woo from Citigroup set a target price of $78.0 on 05/13/2025
- Ed Arce from HC Wainwright & Co. set a target price of $75.0 on 03/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
